Phencyclidine dose optimisation for induction of spatial learning and memory deficits related to schizophrenia in C57BL/6 mice

被引:6
作者
Zain, Mohd Aizat [1 ]
Rouhollahi, Elham [1 ]
Pandy, Vijayapandi [1 ]
Mani, Vasudevan [2 ,3 ]
Majeed, Abu Bakar Abdul [2 ,4 ]
Wong, Won Fen [5 ]
Mohamed, Zahurin [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia
[2] Univ Teknol MARA UiTM, Fac Pharm, Bandar Puncak Alam 42300, Selangor, Malaysia
[3] Qassim Univ, Coll Pharm, Dept Pharmacol & Toxicol, Buraydah 51452, Saudi Arabia
[4] Univ Teknol MARA UiTM, Pharmaceut & Life Sci Core, Shah Alam 40450, Selangor Darul, Malaysia
[5] Univ Malaya, Dept Microbiol, Fac Med, Kuala Lumpur 50603, Malaysia
关键词
learning; maze; memory; phencyclidine; schizophrenia; CORTICAL DOPAMINE; NEGATIVE SYMPTOMS; WATER MAZE; DYSFUNCTION; EXPRESSION; MODELS;
D O I
10.1538/expanim.18-0006
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Phencyclidine (PCP) has been used to model cognitive deficits related to schizophrenia in rats and mice. However, the model in mice is not consistent in terms of the PCP effective dose reported. Furthermore, most of the previous studies in mice excluded the presence of drug washout period in the regime. Thus, we aimed to optimize the dose of PCP in producing robust cognitive deficits by implementing it in a PCP regime which incorporates a drug washout period. The regimen used was 7 days' daily injection of PCP or saline for treatment and vehicle groups, respectively; followed by 24 h drug washout period. After the washout period, the test mice were tested in water maze (5 days of acquisition + 1 day of probe trial) for assessment of spatial learning and memory. Initially, we investigated the effect of PCP at 2mg/kg, however, no apparent impairment in spatial learning and memory was observed. Subsequently, we examined the effect of higher doses of PCP at 5, 10 and 20 mg/kg. We found that the PCP at 10 mg/kg produced a significant increase in "latency to reach the platform" during the acquisition days and a significant increase in "latency of first entry to previous platform" during the probe day. There was no significant change observed in "swim speed" during the test days. Thus, we concluded that PCP at 10 mg/kg produced robust deficits in spatial learning and memory without being confounded by motor disturbances.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 16 条
[1]   Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat (Reprinted from vol 21, pg 198-205, 2007) [J].
Abdul-Monim, Z. ;
Neill, J. C. ;
Reynolds, G. P. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (11) :198-205
[2]  
Baldi Elisabetta, 2005, Nonlinearity in Biology Toxicology and Medicine, V3, P9, DOI 10.2201/nonlin.003.01.002
[3]   Repeated low dose of phencyclidine administration impairs spatial learning in mice:: Blockade by clozapine but not by haloperidol [J].
Beraki, Simret ;
Kuzmin, Alexander ;
Tai, Fadao ;
Ogren, Sven Ove .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (07) :486-497
[4]   Effects of repeated treatment of phencyclidine on cognition and gene expression in C57BL/6 mice [J].
Beraki, Simret ;
Diaz-Heijtz, Rochellys ;
Tai, Fadao ;
Ogren, Sven Ove .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2009, 12 (02) :243-255
[5]   Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL/6J mice [J].
Brigman, Jonathan L. ;
Ihne, Jessica ;
Saksida, Lisa M. ;
Bussey, Timothy J. ;
Holmes, Andrew .
FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2009, 3
[6]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
[7]   Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats [J].
Jentsch, JD ;
Dazzi, L ;
Chhatwal, JP ;
Verrico, CD ;
Roth, RH .
NEUROSCIENCE LETTERS, 1998, 258 (03) :175-178
[8]   Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine [J].
Jentsch, JD ;
Redmond, DE ;
Elsworth, JD ;
Taylor, JR ;
Youngren, KD ;
Roth, RH .
SCIENCE, 1997, 277 (5328) :953-955
[9]   Animal models of schizophrenia [J].
Jones, C. A. ;
Watson, D. J. G. ;
Fone, K. C. F. .
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (04) :1162-1194
[10]   SUBANESTHETIC EFFECTS OF THE NONCOMPETITIVE NMDA ANTAGONIST, KETAMINE, IN HUMANS - PSYCHOTOMIMETIC, PERCEPTUAL, COGNITIVE, AND NEUROENDOCRINE RESPONSES [J].
KRYSTAL, JH ;
KARPER, LP ;
SEIBYL, JP ;
FREEMAN, GK ;
DELANEY, R ;
BREMNER, JD ;
HENINGER, GR ;
BOWERS, MB ;
CHARNEY, DS .
ARCHIVES OF GENERAL PSYCHIATRY, 1994, 51 (03) :199-214